Standard BioTools Inc.
LABHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeStandard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop. Valued at $335.7M, LAB is a small-cap name in its sector. The company operates through Proteomics and Genomics segments.
Market Cap
$335.7M
Beta
1.42
P/E (TTM)
—
P/E (Fwd)
-85.75
EPS (TTM)
$-0.13
EPS (Fwd)
$-0.01
ROE
-9.9%
ROA
-8.1%
Cash
$455.2M
Total Debt
$29.5M
Free CF
-$13.4M
52W Change
-31.2%
Annual Financials
Cash vs Debt
Standard BioTools Inc. holds $455.2M in cash against $29.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$13.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -9.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $97.9M (2022) to $85.3M (2025), a 13% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Standard BioTools Inc.'s trajectory.